GGrantIndex
← Search

AIDS Clinical Trials Group Network

$36,890,085U01FY2008AINIH

Social And Scientific Systems, Inc., Silver Spring MD

Investigators

Linked publications, trials & patents

Paper 39720558Paper 39431507Paper 39400063Paper 39287554Paper 39078109Paper 39036987Paper 38746144Paper 38739755Paper 38684100Paper 38635853Paper 38606559Paper 38556761Paper 38507583Paper 38489580Paper 38215160Paper 38175824Paper 38160309Paper 38006017Paper 37920110Paper 37768207Paper 37741499Paper 37656704Paper 37650236Paper 37650234Paper 37650231Paper 37650230Paper 37503110Paper 37461460Paper 37437108Paper 37292603Paper 37279602Paper 37183889Paper 37099295Paper 37066990Paper 37017075Paper 36922393Paper 36883578Paper 36877848Paper 36802755Paper 36790881Paper 36780493Paper 36661240Paper 36641094Paper 36594946Paper 36549898Paper 36541641Paper 36541638Paper 36540980Paper 36467293Paper 36417366Paper 36378539Paper 36224218Paper 36210483Paper 36129038Paper 36053091Trial NCT02706717Trial NCT01777997Trial NCT01641367Trial NCT01632891Trial NCT01601626Trial NCT01589497Trial NCT01543958Trial NCT01515813Trial NCT01466595Trial NCT01435018Trial NCT01427738Trial NCT01426438Trial NCT01403051Trial NCT01400412Trial NCT01380080Trial NCT01352715Trial NCT01352117Trial NCT01351025Trial NCT01315353Trial NCT01296152Trial NCT01029249Trial NCT00991302Trial NCT00988442Trial NCT00959413Trial NCT00959088Trial NCT00865826Trial NCT00851799Trial NCT00830804Trial NCT00819390Trial NCT00811954Trial NCT00709111Trial NCT00665353Trial NCT00608569Trial NCT00442962Trial NCT00361257Trial NCT00357552Trial NCT00118898Trial NCT00108862Trial NCT00100867Trial NCT00096824Trial NCT00090779Trial NCT00089505Trial NCT00084136Trial NCT00031408Trial NCT00001137

Abstract

[unreadable] DESCRIPTION (provided by applicant): The mission of the AIDS Clinical Trials Group (ACTG) is to develop and conduct scientifically rigorous translational research and therapeutic clinical trials to: 1) investigate the viral and immune pathogenesis of HIV-1 infection and its complications; 2) evaluate novel therapeutic agents and the most effective approaches and strategies for the use of existing agents to treat HIV-1 infection; 3) evaluate interventions and strategies to treat and prevent HIV-related opportunistic infections, co-infections, complications of therapies, and other HIV-1-related co-morbidities, and 4) publish and disseminate the findings from these studies for the purpose of improving clinical care, preventing or delaying HIV disease progression, and reducing or eliminating the morbidity and mortality associated with HIV-1 infection and its associated complications. In this application the ACTG proposes a comprehensive, integrated clinical and translational research program that addresses five of the six scientific areas outlined under this RFA: 1) Translational Research and Drug Development; 2) Optimization of Clinical Management, including Co-Infection; 3) Vaccine Research and Development; 4) Prevention of Mother to Child Transmission, and 5) Prevention of HIV Infection. An Oral Health program will be undertaken in collaboration with investigators supported by the National Institute of Dental and Craniofacial Research. This program will be conducted in collaboration with the HIV Prevention Trials Network (HPTN), the HIV Vaccine Trials Network (HPTN), the IMPAACT network and the Microbicide Trials Network (MTN). The proposed research agenda as well as the Group Leadership and organizational structure reflect the worldwide impact of the HIV epidemic. We propose to conduct the work using a network of 72 clinical research sites in the United States and 12 countries in Africa, Asia, Latin America and the Caribbean. The network is actively supported by an integrated network of Core Laboratories with broad expertise in virology, pharmacology, immunology, and genomics. The ACTG Operations Center, located in Silver Spring, MD, provides key operational, administrative, and fiscal support. Statistical expertise and data management resources are provided by the Statistics and Data Management Center in Boston, MA and Buffalo, NY. [unreadable] [unreadable] [unreadable] CORE (P.I. Benson, Constance) [unreadable] CORE: Translational Research/Drug Development [unreadable] [unreadable] [unreadable]

View original record on NIH RePORTER →